---
figid: PMC5343994__ijms-18-00461-g001
figlink: /pmc/articles/PMC5343994/figure/ijms-18-00461-f001/
number: Figure 1
caption: 'Mutation in the von Hippel–Lindau gene (VHL) induces loss (red ×: HIF-2a
  is no longer inhibited) of the regulatory tumour suppressor p-VHL and catalyses
  the “von Hippel–Lindau-hypoxia-inducible factor” VHL-HIF pathway. Increased expression
  of transcription factor HIF-2α causes (blue arrows) higher levels of growth factors
  (GFs) VEGF, PDGF-β and TGF-α. Sorafenib and sunitinib block their receptors (in
  red TKI effects), and the intracellular Ras/Raf/MEK/ERK cascade (sorafenib) thereby
  inhibiting tumorigenesis and metastasis. Inhibition of GFs leads to a decrease in
  NO-production and reduced endothelial permeability, resulting in increased vasoconstriction,
  total peripheral resistance (TPR), and hypertension (red arrow).'
pmcid: PMC5343994
papertitle: Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment
  of Metastatic Renal Cell Carcinoma.
reftext: Caroline Randrup Hansen, et al. Int J Mol Sci. 2017 Feb;18(2):461.
pmc_ranked_result_index: '103624'
pathway_score: 0.769654
filename: ijms-18-00461-g001.jpg
figtitle: 'Mutation in the von Hippel–Lindau gene (VHL) induces loss (red ×: HIF-2a
  is no longer inhibited) of the regulatory tumour suppressor p-VHL and catalyses
  the “von Hippel–Lindau-hypoxia-inducible factor” VHL-HIF pathway'
year: '2017'
organisms: Homo sapiens
ndex: 0ecf7dab-df2e-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5343994__ijms-18-00461-g001.html
  '@type': Dataset
  description: 'Mutation in the von Hippel–Lindau gene (VHL) induces loss (red ×:
    HIF-2a is no longer inhibited) of the regulatory tumour suppressor p-VHL and catalyses
    the “von Hippel–Lindau-hypoxia-inducible factor” VHL-HIF pathway. Increased expression
    of transcription factor HIF-2α causes (blue arrows) higher levels of growth factors
    (GFs) VEGF, PDGF-β and TGF-α. Sorafenib and sunitinib block their receptors (in
    red TKI effects), and the intracellular Ras/Raf/MEK/ERK cascade (sorafenib) thereby
    inhibiting tumorigenesis and metastasis. Inhibition of GFs leads to a decrease
    in NO-production and reduced endothelial permeability, resulting in increased
    vasoconstriction, total peripheral resistance (TPR), and hypertension (red arrow).'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - MAP2K2
  - KDR
  - VEGFA
  - EPAS1
  - MAP2K1
  - TPR
  - MAPK1
  - VEGFB
  - VEGFC
  - PDGFB
  - PGF
  - FLT4
  - FLT1
  - ARAF
  - VEGFD
  - KRAS
  - MAPK3
  - NRAS
  - TGFA
  - VHL
  - RAF1
  - BRAF
  - HRAS
  - Cancer
  - Cardiomyopathy
  - Noonan syndrome
genes:
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: KDR
  entrez: '3791'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFA
  entrez: '7422'
- word: HIF-2a
  symbol: HIF2A
  source: hgnc_alias_symbol
  hgnc_symbol: EPAS1
  entrez: '2034'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: TPR
  symbol: TPR
  source: hgnc_symbol
  hgnc_symbol: TPR
  entrez: '7175'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFB
  entrez: '7423'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFC
  entrez: '7424'
- word: PDGF-B
  symbol: PDGFB
  source: hgnc_symbol
  hgnc_symbol: PDGFB
  entrez: '5155'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: PGF
  entrez: '5228'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: FLT4
  entrez: '2324'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: FLT1
  entrez: '2321'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFD
  entrez: '2277'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: TGF-a
  symbol: TGFA
  source: hgnc_symbol
  hgnc_symbol: TGFA
  entrez: '7039'
- word: p-VHL
  symbol: VHL
  source: hgnc_symbol
  hgnc_symbol: VHL
  entrez: '7428'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
chemicals: []
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
---
